רווח תפעולי לפני ניכוי פחת: organon.com (OGN)

Stable demand for mature brands ensures a steady cash flow, as confirmed by the total EBITDA for Organon & Co. (OGN). The value 1541.09 is recorded as the baseline value for this indicator. Profit growth is driven by global sales of well-known medications with minimal costs, as well as strategic alliances with biotech centers to introduce innovative drugs.

The cash flow stability of Organon & Co. (OGN) is being tested by its ability to generate profit amid R&D expenditures for women's health drugs and the expansion of its biosimilars portfolio. By analyzing the EBITDA_Co level on the GURU.Markets chart, an investor can see the net operating mass before taxes, which allows for an assessment of the core business's real efficiency and capital predictability before accounting for debt load.